Therapeutic Relevance of Cannabinoids for Alzheimer's Disease

大麻素对阿尔茨海默病的治疗意义

基本信息

项目摘要

Alzheimer's disease (AD) is the most prevalent old age-associated neurodegenerative disease. However, despite extensive interest and financial outlay, drug discovery in this area has not yet yielded any disease modifying compounds. This may be in part due to the small number of molecular targets suitable for drug discovery. Thus, the identification of multiple, new drug targets is still one of the most important challenges. Natural products are the structural basis of the majority of the drugs in the clinic today. Over the last decade we have used a novel phenotypic drug-screening platform based upon toxicities associated with the old brain and natural product chemical libraries and plant extracts to identify compounds that have therapeutic efficacy in multiple models of neurodegeneration and dementia. Structure-activity relationship driven medicinal chemistry was then used to make pharmacologically suitable drug candidates. One of these compounds is in Phase I clinical trials for AD and another has NIH funding for investigational new drug (IND) studies. Perhaps the greatest relatively unexplored area of AD drug discovery is the endocannabinoid system and the compounds in the Cannabis plant that may interact with it and other pathways associated with neurodegeneration. While THC and CBD are the best-studied chemicals in Cannabis, there are over 100 non-psychoactive cannabinoids and 400 other unique chemicals within the plant that may have therapeutic potential. We have recently demonstrated that several of these compounds are exceptionally neuroprotective in our drug screening platform that has already yielded bona fide AD drug candidates. The hypothesis for this high risk, high reward R21 application is that there are non-psychoactive compounds within the Cannabis plant that are suitable lead drug candidates for AD, and that these can be identified, along with their molecular targets, by our drug screening platform and chemical proteomics, respectively. There are three Specific Aims in this application. 1) All commercially available pure cannabinoids, flavones and terpenes in Cannabis, will be screened, a project already underway. In collaboration with Dr. ElSohly at the University of Mississippi, additional pure compounds will be screened that he has isolated as well as complex high CBD Cannabis (hemp) extracts where the most active new compounds will be identified. The pharmacological and safety properties of the five best compounds will be studied. 2) The molecular targets of one will be determined. 3) Finally, the therapeutic efficacy of the best compound will be examined in the 3xFAD transgenic mouse model of familial AD and rapidly aging SAMP8 mice. At the end of two years, a non-psychoactive compound and its target will have been identified and tested in two rigorous models of dementia, gaining a greater understanding of the therapeutic potential of Cannabis as well as identifying a novel lead AD drug candidate and its molecular target.
阿尔茨海默病(AD)是最常见的老年相关神经退行性疾病。然而, 尽管有广泛的兴趣和资金投入,但这一领域的药物发现尚未产生任何疾病 修饰化合物。这在一定程度上可能是由于适用于药物的分子靶标数量较少。 发现号。因此,确定多个新的药物靶点仍然是最重要的挑战之一。 天然产物是当今临床上大多数药物的结构基础。在过去的十年里 我们使用了一种新的表型药物筛选平台,该平台基于与旧脑相关的毒性 和天然产品化学库和植物提取物,以确定具有治疗效果的化合物 在多种神经变性和痴呆症模型中。构效关系驱动型药物 然后,化学被用来制造药理上合适的候选药物。其中一种化合物在 AD的第一阶段临床试验和NIH为研究性新药(IND)研究提供资金的另一阶段。 也许AD药物发现中最大的相对未被探索的领域是内源性大麻系统 大麻植物中可能与之相互作用的化合物以及与之相关的其他途径 神经退行性变。虽然THC和CBD是大麻中研究最深入的化学物质,但有100多种 植物中的非精神活性大麻素和400种其他独特的化学物质可能具有治疗作用 潜力。我们最近证明了其中几种化合物具有特殊的神经保护作用。 在我们的药物筛选平台上,已经产生了真正的AD候选药物。假设 这种高风险、高回报的R21应用是在 大麻植物,适合作为AD的候选铅药物,这些植物可以被识别,以及 与其分子靶点,分别由我们的药物筛选平台和化学蛋白质组学。 这个应用程序有三个具体目标。1)所有市面上可买到的纯大麻类药物, 将对大麻中的黄酮类和萜类进行筛选,这一项目已经在进行中。与Dr. ElSohly在密西西比大学,将筛选出更多的纯化合物,他已经分离出 以及复杂的高CBD大麻(大麻)提取物,其中最活跃的新化合物将是 确认身份。将对这五种最佳化合物的药理和安全性进行研究。2) 其中一个的分子靶标将被确定。3)最后,最佳化合物的治疗效果将是 在家族性AD和快速老化的SAMP8小鼠的3xFAD转基因小鼠模型中进行了检测。在…的末尾 两年内,一种非精神活性化合物及其靶标将在两年内被确定和测试 严格的痴呆症模型,更好地了解 以及确定一种新的AD候选药物及其分子靶点。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Pamela Anne Maher其他文献

Pamela Anne Maher的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Pamela Anne Maher', 18)}}的其他基金

Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease
阿尔茨海默病新候选治疗药物 CMS121 的 1 期临床试验
  • 批准号:
    10307970
  • 财政年份:
    2021
  • 资助金额:
    $ 52.91万
  • 项目类别:
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease
阿尔茨海默病新候选治疗药物 CMS121 的 1 期临床试验
  • 批准号:
    10553057
  • 财政年份:
    2021
  • 资助金额:
    $ 52.91万
  • 项目类别:
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease
阿尔茨海默病新候选治疗药物 CMS121 的 1 期临床试验
  • 批准号:
    10542565
  • 财政年份:
    2021
  • 资助金额:
    $ 52.91万
  • 项目类别:
Using geroscience to understand and treat Alzheimer's disease
利用老年科学来理解和治疗阿尔茨海默病
  • 批准号:
    10432126
  • 财政年份:
    2020
  • 资助金额:
    $ 52.91万
  • 项目类别:
Using geroscience to understand and treat Alzheimer's disease
利用老年科学来理解和治疗阿尔茨海默病
  • 批准号:
    10054924
  • 财政年份:
    2020
  • 资助金额:
    $ 52.91万
  • 项目类别:
Using geroscience to understand and treat Alzheimer's disease
利用老年科学来理解和治疗阿尔茨海默病
  • 批准号:
    10266116
  • 财政年份:
    2020
  • 资助金额:
    $ 52.91万
  • 项目类别:
Using geroscience to understand and treat Alzheimer's disease
利用老年科学来理解和治疗阿尔茨海默病
  • 批准号:
    10621213
  • 财政年份:
    2020
  • 资助金额:
    $ 52.91万
  • 项目类别:
A Novel Drug Candidate for the Treatment of Huntington's Disease
治疗亨廷顿病的新候选药物
  • 批准号:
    9751981
  • 财政年份:
    2018
  • 资助金额:
    $ 52.91万
  • 项目类别:
Identification of Old-Age-Associated Alzheimer's Disease Drug Targets
老年相关阿尔茨海默病药物靶点的鉴定
  • 批准号:
    9064733
  • 财政年份:
    2014
  • 资助金额:
    $ 52.91万
  • 项目类别:
Identification of Old-Age-Associated Alzheimer's Disease Drug Targets
老年相关阿尔茨海默病药物靶点的鉴定
  • 批准号:
    8605370
  • 财政年份:
    2014
  • 资助金额:
    $ 52.91万
  • 项目类别:

相似海外基金

How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.91万
  • 项目类别:
    Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 52.91万
  • 项目类别:
    Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 52.91万
  • 项目类别:
    Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.91万
  • 项目类别:
    Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 52.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.91万
  • 项目类别:
    Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 52.91万
  • 项目类别:
    Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 52.91万
  • 项目类别:
    Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
  • 批准号:
    23K00129
  • 财政年份:
    2023
  • 资助金额:
    $ 52.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
  • 批准号:
    2883985
  • 财政年份:
    2023
  • 资助金额:
    $ 52.91万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了